European Healthtech Grabs The Investor Headlines In H1 2022
Cautious Optimism For Sector And M&A Set To Stay Strong In 2022
Executive Summary
After a runaway 2021 and a strong if bumpy first quarter of 2022, all health care product sectors underwent an investment dip in the second quarter, says Silicon Valley Bank. Healthtech in Europe remained a stand-out performer.
You may also be interested in...
‘The Story That No One Likes To Hear’: Investors Looking For Surer Bets In Health Tech After Record 2021
A panel of investors and leaders in healtech expects investment in health tech to decline, but still foresees opportunities for companies working on solutions that will transform overall health care such as AI, ML, mental health and health equity.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.